Erin D. Michos

3 weeks ago | trialsjournal.biomedcentral.com | Samuel Byiringiro |Juliana Garcia |Hailey Miller |Evans M. Whitaker |Barbara E. Bierer |Erin D. Michos | +13 more

The lack of diversity in clinical studies has significant ethical and health consequences, limiting the development of effective treatments for diverse populations. Homogeneous participation in clinical studies contributes to health disparities, particularly among historically underrepresented groups in the United States (US). Racial, ethnic, and other minoritized populations have long been excluded from clinical research. In response, the US Congress mandated the National Institutes of Health to assess the impacts of insufficient diversity in clinical studies. Despite efforts by the government, non-profit organizations, and industry players to improve diversity in clinical studies, progress has been slow due to fragmented approaches. For instance, the new US administration (2025) has recently released executive orders which threaten to reverse the progress made in inclusive clinical research. The Stanford Think Tank on Diversity and Equity in Clinical Trials, held in September 2023, brought together key partners across multiple sectors and professions to discuss barriers and explore potential solutions to participation in clinical studies. In this commentary, we discuss the importance of collaborative, inclusive strategies in clinical study design to advance equitable health outcomes for all. Further, we discuss potential implications of the government’s dismissal of diversity, equity, and inclusion initiatives on diverse research participation.

Nov 16, 2024 | healio.com | Regina Schaffer |Richard Smith |Erin D. Michos |Milton Packer

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC Patients with the obesity phenotype represent the majority of those with HF with preserved ejection fraction — increased plasma volume and stressed blood volume, more concentric left ventricular remodeling, high prevalence of hypertension, more right ventricular dysfunction, increased epicardial fat thickness, higher total epicardial heart volume, and are more diuretic resistant.

Oct 21, 2024 | healio.com | Scott Buzby |Erin D. Michos |Erik Swain

Read more You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — In this Healio video exclusive, Erin D.

Oct 1, 2024 | radcliffecardiology.com | Sanjiv Shah |Erin D. Michos |Alison Bailey |Tina Ticinovic Kurir

Video Published: Views: 2 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892). EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.

Jun 10, 2024 | healio.com | Erin D. Michos |Scott Buzby

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PHILADELPHIA — In this Healio video exclusive, Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC, highlights the need for greater prevention of myocardial infarction and cardiovascular death in young women.